4.7 Article

Nonpeptidic and Potent Small-Molecule Inhibitors of cIAP-1/2 and XIAP Proteins

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 17, Pages 6361-6367

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm100487z

Keywords

-

Funding

  1. National Cancer Institute, National Institutes of Health [R01CA109025]
  2. Breast Cancer Research Foundation
  3. Susan G. Komen Foundation
  4. University of Michigan Cancer Center [P30CA046592]

Ask authors/readers for more resources

A series of compounds were designed and synthesized as antagonists of cIAP-1/2 and XIAP based upon our previously identified lead compound SM-122 (1). The most potent of these (7) binds to XIAP, cIAP-1, and cIAP-2 proteins with K(i) values of 36, <1, and <1.9 nM, respectively. Consistent with its potent binding affinities to IAPs, 7 effectively antagonizes XIAP in a cell-free caspase-9 functional assay, efficiently induces cIAP-1 degradation in cells at concentrations as low as 10 nM, and triggers activation of caspases and PARP cleavage in the MDA-MB-231 breast cancer cell line. Compound 7 potently inhibits cell growth in the MDA-MB-231 cancer cell line with an IC(50) value of 200 nM and is 9 times more potent than compound 1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available